Fundraising FoxGradalis
Carrollton, US · Founded 2014 · Delaware corporation · 2 known investors
Find your way into Gradalis
Each arrow is one introduction. Sign up to fill in the first one.
12 people can intro you to Gladice
Ask Scott Gottlieb to introduce you to Gladice Wallraven
You →Scott · together at Gradalis →Gladice
Sign up to find every way you can get introduced to Gradalis
- Your email: who you already know at Gradalis, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Gradalis team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Gradalis develops Vigil, a patient-specific immunotherapy studied in research and clinical trials for treating ovarian cancer, with potential use in other solid tumors. The therapy can be used on its own or alongside other cancer treatments.
Founders & leadership
Gradalis was founded in 2014 by John Nemunaitis and Shanahan.
JN
John NemunaitisChief Scientific Officer and Co-Founder
S
ShanahanFounder and Chairman
DM
David M. ShanahanFounder and Chairman
EB
Ernest BognarExecutive
GW
Gladice WallravenSVP Clinical and Regulatory OperationsWallraven has over 20 years of experience in clinical research, with a focus on regulatory affairs and early and late phase trials of novel agents. She is now an Executive Officer at Gradalis, which develops Vigil, a patient-specific immunotherapy for ovarian cancer and other solid tumors.
RL
Renee LarsonExecutive
JN
John Nemunaitis, M.D.Named on SEC filing
Board
HR
Harry R. JacobsonBoard director
JC
Joe C. CunninghamBoard director
JF
Investors · 2
WP Global Partnerslisted by WP Global PartnersChicago · $5M – $25M
How we know: funding news · Not right? Tell us
Funding
SEC filings, press & company announcements$56.7M disclosed across 2 of 3 rounds · 2013–2025
- Undisclosed amountSeries BJan 2013Source ↗
▶$12.7MraisedJun 2025 · 24 investors · BiotechnologyRule 506(b)
▶$12.7MraisedJun 2025 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John NemunaitisExecutive Officer, Director
- Harry R. JacobsonDirector
- Joe C. CunninghamDirector
- Joseph F. BerryDirector
- Robert P. LandinDirector
- David M. ShanahanExecutive Officer, Director
- Scott SeamanDirector
- Mark EarlyExecutive Officer
- Offering amount
- $30M
- Amount sold
- $12.7M
- Minimum investment
- $250K
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$43.9MraisedApr 2018 · 36 investors · PharmaceuticalsRule 506(b)
▶$43.9MraisedApr 2018 · 36 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ernest BognarExecutive Officer
- David ShanahanExecutive Officer, Director
- Gladice WallravenExecutive Officer
- Joe Cunningham, M.D.Director
- Harry Jacobson, M.D.Director
- Robert LandinDirector
- Thomas LylesDirector
- John Nemunaitis, M.D.Executive Officer, Director
- Renee LarsonExecutive Officer
- Scott SeamanDirector
- Offering amount
- $55M
- Amount sold
- $43.9M
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 8
GenialisGenialis is a precision oncology company that applies data analysis to help drug developers understand mechanisms of action, resistance, and patient stratification for cancer therapies. It supports pharmaceutical partners in advancing molecules through clinical trials toward becoming effective medicines.
AlumisAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
ZentalisZentalis is a biopharmaceutical company developing azenosertib and other pipeline assets, seeking strategic partnerships to advance drug development and expand market reach globally.
Parabilis MedicinesHelicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules. The platform uses AI and simulation to engineer helical peptides with non-canonical amino acids for precision binding across a range of therapeutic applications.
PrellisPrellis Biologics runs an antibody discovery platform that uses two-photon laser-bioprinted human immune organoids combined with machine learning to identify fully human antibody therapeutics. It develops a portfolio of antibody drug candidates across multiple disease areas and partners with biotech and pharmaceutical companies.
株式会社モダリスModalis Therapeutics develops therapeutics using CRISPR gene-editing technology and provides its platform technology for drug development. It operates in the biotechnology sector.
GrailGRAIL develops the Galleri blood test for multi-cancer early detection using next-generation sequencing and machine learning to screen for multiple deadly cancer types before symptoms appear. The test is offered by prescription in the United States and through partnerships with healthcare systems, insurance carriers, and diagnostic platforms.
ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
Companies working in the same space as Gradalis.
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2011 | $650K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $199K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2006 | $124.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2006 | $124.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Gradalis do?
- Gradalis develops Vigil, a patient-specific immunotherapy studied in research and clinical trials for treating ovarian cancer, with potential use in other solid tumors. The therapy can be used on its own or alongside other cancer treatments.
- Who founded Gradalis?
- Gradalis was founded by John Nemunaitis, Shanahan in 2014.
- Who are Gradalis's investors?
- Gradalis's investors include WP Global Partners, WP Explorer.
- How much funding has Gradalis raised?
- Gradalis has disclosed $56.7M raised across 2 of its 3 known rounds.
- Where is Gradalis headquartered?
- Gradalis is headquartered in Carrollton, US.